Anthropic Is Expected to Go Public in October. The Brokerages Get Paid Either Way.

Goldman Sachs and Morgan Stanley are reportedly lead advisors on Anthropic's potential October IPO, which could raise up to $100 billion at a $2 trillion valuation. The article estimates the deal could generate fees comparable to or above the $500 million pool from SpaceX's IPO, where Goldman and Morgan Stanley reportedly earned $100 million each. Goldman shares are down 15% from their July high and Morgan Stanley is down about 10%, while median price targets imply 23% and 20% upside, respectively.

Analysis

The underwriting economics alone are too small to justify a durable rerating in GS or MS: even a nine-figure advisory allocation is a low-single-digit contribution to quarterly investment-banking revenue and materially less after compensation accruals. The investable signal is instead whether a marquee AI listing reopens the sponsor/late-stage technology issuance calendar, driving follow-on equity issuance, converts and M&A mandates over the subsequent 6-18 months. GS has greater operating leverage to that outcome through its institutional franchises; MS captures less pure underwriting upside but can monetize secondary liquidity, founder wealth management and employee equity-plan assets.

Near-term, this is a positioning and estimates-revision trade rather than a fee trade. A successful deal could lift 2027 global-IB fee forecasts for GS, MS, JPM, BAC and C over the next 1-3 months, but current valuations already embed a healthy capital-markets cycle and Q3 results will be dominated by trading, debt issuance and compensation ratios. The more differentiated second-order beneficiary is KKR/ARES/BX if the transaction resets private-AI marks and releases liquidity for LPs; that effect requires a clean aftermarket, not merely pricing.

Consensus appears to extrapolate a single transaction while underweighting execution risk: issuer valuation, allocation quality, lockup supply and broader AI multiple dispersion can all impair aftermarket performance. A weak debut would likely hurt the banks less on direct P&L than on the narrative that the IPO window is sustainably open, producing a sharper de-rating in alternative-asset managers and late-stage software comparables. Verify lead-left status, expected fee pool and timing through filings before treating reported mandates as forecastable revenue.

Key Decisions for Investors

• Initiate a 1-3 month tactical long GS / short MS pair only if GS underperforms MS into verified launch timing; target 5-8% relative upside from GS's higher capital-markets operating leverage. Exit if GS reports weaker-than-peer advisory backlog or compensation ratio expansion offsets revenue growth.
• Prefer long GS versus a diversified bank basket (KBE) rather than outright exposure through the pricing/roadshow window; the trade isolates issuance upside from rate and credit-beta risk. Size modestly because a single mandate is not earnings-material; stop on a 7% relative drawdown.
• Place an alert to add KKR or ARES after a verified deal prices above the indicated range and holds above issue price for 10 trading days. The catalyst is private-mark revaluation and improved realization expectations over 6-18 months; do not pre-position on valuation headlines alone.
• Avoid chasing BAC, C, JPM or BCS solely on ancillary-book participation: without disclosed allocation or fee economics, the incremental revenue is unlikely to move consensus EPS. Reassess only if subsequent technology IPO filings demonstrate a broader issuance pipeline.